HHS Drug Pricing Plan: Mum On National Cost Effectiveness Program, Cautious On QALYs

Biopharma likely approves of the Administration’s concern that QALYs, a commonly used metric in cost effectiveness evaluations, may not be appropriate for drug pricing reform policies because it could disadvantage people with disabilities.